Janux Therapeutics (NASDAQ:JANX) Upgraded by Truist Financial to Strong-Buy Rating

Truist Financial upgraded shares of Janux Therapeutics (NASDAQ:JANX) to a strong-buy rating in a report issued on Monday,Zacks.com reports.

Several other equities research analysts also recently weighed in on the company. Barclays downgraded Janux Therapeutics from an “overweight” rating to an “underweight” rating and decreased their target price for the stock from $29.00 to $14.00 in a research report on Monday, April 20th. Wall Street Zen raised Janux Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, April 5th. Piper Sandler decreased their target price on Janux Therapeutics from $42.00 to $30.00 and set an “overweight” rating for the company in a research report on Friday, January 16th. Guggenheim decreased their target price on Janux Therapeutics from $72.00 to $68.00 and set a “buy” rating for the company in a research report on Friday, February 27th. Finally, UBS Group downgraded Janux Therapeutics from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $57.00 to $15.00 in a research report on Wednesday, April 15th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Janux Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $49.75.

Janux Therapeutics Trading Up 0.3%

NASDAQ:JANX traded up $0.05 on Monday, hitting $14.47. 163,727 shares of the stock were exchanged, compared to its average volume of 1,221,516. The stock has a market cap of $881.79 million, a PE ratio of -7.91 and a beta of 2.58. The stock has a fifty day moving average of $14.29 and a 200-day moving average of $17.72. Janux Therapeutics has a fifty-two week low of $12.12 and a fifty-two week high of $35.34.

Janux Therapeutics (NASDAQ:JANX) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($0.51) EPS for the quarter, topping the consensus estimate of ($0.65) by $0.14. The firm had revenue of $7.88 million for the quarter, compared to analyst estimates of $0.08 million. As a group, analysts predict that Janux Therapeutics will post -2.34 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Nano Cap New Millennium Growth Fund L P acquired a new stake in Janux Therapeutics in the 4th quarter valued at approximately $34,000. Caitong International Asset Management Co. Ltd acquired a new stake in Janux Therapeutics in the 4th quarter valued at approximately $51,000. Osaic Holdings Inc. increased its position in Janux Therapeutics by 704.6% in the 2nd quarter. Osaic Holdings Inc. now owns 3,468 shares of the company’s stock valued at $80,000 after acquiring an additional 3,037 shares during the period. Tower Research Capital LLC TRC increased its position in Janux Therapeutics by 175.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 3,928 shares of the company’s stock valued at $91,000 after acquiring an additional 2,502 shares during the period. Finally, Winthrop Capital Management LLC bought a new position in Janux Therapeutics during the 3rd quarter valued at $106,000. 75.39% of the stock is currently owned by institutional investors.

Janux Therapeutics Company Profile

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.